Soluble P-selectin and thrombomodulin-protein C-Protein S pathway in cyanotic congenital heart disease with secondary erythrocytosis

Thrombosis Research

Volumn 112, Issue 4, 2003, Pages 223-227

  Horigome, Hitoshi ^a   Murakami, Takashi ^a   Isobe, Takeshi ^b   Nagasawa, Toshiro ^a   Matsui, Akira ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b Ibaraki Children's Hospital   (Japan)

Author keywords

Coagulation disorder; Cyanotic congenital heart disease; Erythrocytosis; P selectin; Thrombomodulin protein C protein S pathway

Indexed keywords

BETA THROMBOGLOBULIN; PADGEM PROTEIN; PROTEIN C; PROTEIN S; THROMBOCYTE FACTOR 4; THROMBOMODULIN;

ADULT; ARTICLE; BLOOD CLOTTING DISORDER; CLINICAL ARTICLE; CONGENITAL HEART DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYANOTIC HEART DISEASE; ERYTHROCYTOSIS; EVALUATION; HEMATOCRIT; HUMAN; PATHOGENESIS; PATIENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SOLUBILITY; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOSIS;

EID: 1342345208     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2003.12.011     Document Type: Article

References (32)

1. Perloff J.K., Rosove M.H., Sietsema K.E., Territo M.C. Cyanotic congenital heart disease: a multisystem disorder. Perloff J.K., Child J.S. Congenital heart disease in adults. 2nd ed. 1998;199-226 Saunders, Philadelphia, PA.
2. Levin E., Wu J., Devine D.V., Alexander J., Reichart C., Sett S.et al. Hemostatic parameters and platelet activation marker expression in cyanotic and acyanotic pediatric patients undergoing cardiac surgery in the presence of tranexamic acid. Thromb. Haemost. 83:2000;54-59.
3. Adatia I., Barrow S.E., Stratton P., Ritter J.M., Haworth S.G. Abnormalities in the biosynthesis of thromboxane A2 and prostacyclin in children with cyanotic congenital heart disease. Br. Heart J. 69:1993;179-182.
4. Olgun N., Uysal K.M., Irken G., Unal N., Undar B., Akkoc N.et al. Platelet activation in congenital heart diseases. Acta Paediatr. Jpn. 39:1997;566-569.
5. Sakariassen K.S., Holme P.A., Orvim U., Barstad R.M., Solum N.O., Brosstad F.R. Shear-induced platelet activation and platelet microparticle formation in native human blood. Thromb. Res. 92:1998;S33-S41.
6. Ferreiro C.R., Chagas A.C.P., Carvalho M.H., Dantas A.P., Jatene M.B., Bento De Souza L.C.et al. Influence of hypoxia on nitric oxide synthase activity and gene expression in children with congenital heart disease. A novel pathophysiological adaptive mechanism. Circulation. 103:2001;2272-2276.
7. McLeod K.A., Martin P., Williams G., Walker D.R. Neutrophil activation and morbidity in young adults with cyanotic congenital heart disease. Blood Coagul. Fibrinolysis. 5:1994;17-22.
8. Perloff J.K., Marelli A.J., Miner P.D. Risk of stroke in adults with cyanotic congenital heart disease. Circulation. 87:1993;1954-1959.
9. Ammash N., Warnes C.A. Cerebrovascular events in adult patients with cyanotic congenital heart disease. J. Am. Coll. Cardiol. 28:1996;768-772.
10. Tempe D.K., Virmani S. Coagulation abnormalities in patients with cyanotic congenital heart disease. J. Cardiothorac. Vasc. Anesth. 16:2002;752-765.
11. Starnes S.L., Duncan B.W., Kneebone J.M., Rosenthal G.L., Jones T.K., Grifka R.G.et al. Vascular endothelial growth factor and basic fibroblast growth factor in children with cyanotic congenital heart disease. J. Thorac. Cardiovasc. Surg. 119:2000;534-539.
12. Horigome H., Hiramatsu Y., Shigeta O., Nagasawa T., Matsui A. Overproduction of platelet microparticles in cyanotic congenital heart disease with polycythemia. J. Am. Coll. Cardiol. 39:2002;1072-1077.
13. Michelson A.D., Barnard M.R., Hechtman H.B., MacGregor H., Connolly R.J., Loscalzo J.et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc. Natl. Acad. Sci. U. S. A. 93:1996;11877-11882.
14. Frenette P.S., Johnson R.C., Hynes R.O., Wagner D.D. Platelet roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc. Natl. Acad. Sci. U. S. A. 92:1995;7450-7454.
15. Merten M., Chow T., Hellums J.D., Thiagarajan P. A new role for P-selectin in shear-induced platelet aggregation. Circulation. 102:2000;2045-2050.
16. Ihenacho H.N.C., Fletcher D.J., Breeze G.R., Stuart J. Consumption coagulopathy in congenital heart-disease. Lancet. 1(7797):1974;231-234.
17. Blann A.D., Lip G.Y., Beevers D.G., McCollum C.N. Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Thromb. Haemost. 77:1997;1077-1080.
18. Jilma B., Fasching P., Ruthner C., Rumplmayr A., Ruzicka S., Kapiotis S.et al. Elevated circulating P-selectin in insulin dependent diabetes mellitus. Thromb. Haemost. 76:1996;328-332.
19. Lip G.Y., Blann A.D., Zarifis J., Beevers M., Lip P.L., Beevers D.G. Soluble adhesion molecule P-selectin and endothelial dysfunction in essential hypertension: implications for atherogenesis? A preliminary report. J. Hypertens. 13:1995;1674-1678.
20. Sakamaki F., Kyotani S., Nagaya N., Sato N., Oya H., Satoh T.et al. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy. Circulation. 102:2000;2720-2725.
21. Komai H., Haworth S.G. Effect of cardiopulmonary bypass on the circulation level of soluble GMP-140. Ann. Thorac. Surg. 58:1994;478-482.
22. Rakusan K., Cicutti N., Kolar F. Cardiac function, microvascular structure, and capillary hematocrit in hearts of polycythemic rats. Am. J. Physiol. Heart Circ. Physiol. 281:2001;H2425-H2431.
23. Welsh C.H., Hassell K.L., Badesch D.B., Kressin D.C., Marlar R.A. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest. 110:1996;710-717.
24. Maruyama I. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Thromb. Haemost. 82:1999;718-721.
25. Levi M., Ten Cate H. Disseminated intravascular coagulation. N. Engl. J. Med. 341:1999;586-592.
26. Boffa M.C., Karmochkine M. Thrombomodulin: an overview and potential implication in vascular disorders. Lupus. 7(Suppl. 2):1998;S120-S125.
27. Malek A.M., Jackman R., Rosenberg R.D., Izumo S. Endothelial expression of thrombomodulin is reversibly regulated by fluid shear stress. Circ. Res. 74:1994;852-860.
28. Cadroy Y., Diquelou A., Dupouy D., Bossavy J.P., Sakariassen K.S., Sie P.et al. The thrombomodulin/protein C/protein S anticoagulant pathway modulates the thrombogenic properties of the normal resting and stimulated endothelium. Arterioscler. Thromb. Vasc. Biol. 17:1997;520-527.
29. Esmon C. The protein C pathway. Crit. Care Med. 28:2000;S44-S48. [Suppl.].
30. Zoppi M., Furlan M., Brun del Re G., Wuillemin W., Lammle B. Decreased free protein S levels in polycythemia vera. Thromb. Haemost. 64:1990;177-178.
31. Bucalossi A., Marotta G., Bigazzi C., Galieni P., Dispensa E. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. Am. J. Hematol. 52:1996;14-20.
32. Neunteufl T., Heher S., Stefenelli T., Pabinger I., Gisslinger H. Endothelial dysfunction in patients with polycythemia vera. Br. J. Haematol. 115:2001;354-359.